Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles: Therapeutics, Targets, and Development

Metastasis is strongly reduced by the matrix metalloproteinase inhibitor Galardin in the MMTV-PymT transgenic breast cancer model

Kasper Almholt, Anna Juncker-Jensen, Ole Didrik Lærum, Keld Danø, Morten Johnsen, Leif Røge Lund and John Rømer
Kasper Almholt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Juncker-Jensen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ole Didrik Lærum
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keld Danø
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Morten Johnsen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leif Røge Lund
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Rømer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-08-0251 Published September 2008
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: September 2008 to March 2021

AbstractFull-text HTMLPDF
Total231539782192

Cited By

Article Information

Volume 7, Issue 9, pp. 2758-2767

DOI 
https://doi.org/10.1158/1535-7163.MCT-08-0251
PubMed 
18790756

Published By 
American Association for Cancer Research
Print ISSN 
1535-7163
Online ISSN 
1538-8514
History 
  • June 15, 2008
  • March 14, 2008
  • June 13, 2008
  • Published first September 11, 2008.

Copyright & Usage 
American Association for Cancer Research

Author Information

  1. Kasper Almholt1,
  2. Anna Juncker-Jensen1,
  3. Ole Didrik Lærum3,
  4. Keld Danø1,
  5. Morten Johnsen2,
  6. Leif Røge Lund1 and
  7. John Rømer1
  1. 1Finsen Laboratory, Rigshospitalet, and 2Department of Molecular Biology, University of Copenhagen, Copenhagen Biocenter, Copenhagen, Denmark and 3The Gade Institute, Section of Pathology, Haukeland University Hospital, Bergen, Norway
  1. Requests for reprints: Leif Røge Lund, Finsen Laboratory, Rigshospitalet 3735, Copenhagen Biocenter, Ole Maaløes Vej 5, DK-2200 Copenhagen, Denmark. Phone: 45-3545-6047; Fax: 45-3545-3797. E-mail: lund{at}inet.uni2.dk
View Full Text
PreviousNext
Back to top
Molecular Cancer Therapeutics: 7 (9)
September 2008
Volume 7, Issue 9
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Metastasis is strongly reduced by the matrix metalloproteinase inhibitor Galardin in the MMTV-PymT transgenic breast cancer model
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Metastasis is strongly reduced by the matrix metalloproteinase inhibitor Galardin in the MMTV-PymT transgenic breast cancer model
Kasper Almholt, Anna Juncker-Jensen, Ole Didrik Lærum, Keld Danø, Morten Johnsen, Leif Røge Lund and John Rømer
Mol Cancer Ther September 1 2008 (7) (9) 2758-2767; DOI: 10.1158/1535-7163.MCT-08-0251

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Metastasis is strongly reduced by the matrix metalloproteinase inhibitor Galardin in the MMTV-PymT transgenic breast cancer model
Kasper Almholt, Anna Juncker-Jensen, Ole Didrik Lærum, Keld Danø, Morten Johnsen, Leif Røge Lund and John Rømer
Mol Cancer Ther September 1 2008 (7) (9) 2758-2767; DOI: 10.1158/1535-7163.MCT-08-0251
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors
  • Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors
  • WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells
Show more Research Articles: Therapeutics, Targets, and Development
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement